4.8 Article

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 114, Issue 2, Pages 270-279

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200421275

Keywords

-

Funding

  1. NIAID NIH HHS [U01 AI056453, P01 AI040682, AI56453, AI40682] Funding Source: Medline
  2. NIAMS NIH HHS [P30 AR047360, AR47360] Funding Source: Medline
  3. NIDDK NIH HHS [DK35108, P01 DK035108] Funding Source: Medline

Ask authors/readers for more resources

Epidemiological evidence points to the inverse relationship between microbial exposure and the prevalence of allergic asthma and autoimmune diseases in Westernized countries. The molecular basis for this observation has not yet been completely delineated. Here we report that the administration of certain toll-like receptor (TLR) ligands, via the activation of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism in various organs. TLR9 ligand-induced pulmonary IDO activity inhibits Th2-driven experimental asthma. IDO activity expressed by resident lung cells rather than by pulmonary DCs suppressed lung inflammation and airway hyperreactivity. Our results provide a mechanistic insight into the various formulations of the hygiene hypothesis and underscore the notion that activation of innate immunity can inhibit adaptive Th cell responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available